SCHEMBL718360

SCHEMBL718360

CNc1cnc2cc3c(cc2n1)CCNCC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.41
HTR2B P41595 8/20 0.38
ADCY6 O43306 1/20 0.37
ADCY3 O60266 1/20 0.37
ADCY9 O60503 1/20 0.37
ADCY5 O95622 1/20 0.37
ADCY8 P40145 1/20 0.37
ADCY7 P51828 1/20 0.37
ADCY2 Q08462 1/20 0.37
ADCY1 Q08828 1/20 0.37
ADCY4 Q8NFM4 1/20 0.37
PDGFRB P09619 8/20 0.36
PDGFRA P16234 8/20 0.36
HTR2C P28335 7/20 0.35
HTR2A P28223 4/20 0.34
EGFR P00533 1/20 0.34
INSR P06213 1/20 0.34
LCK P06239 1/20 0.34
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL718879 0.87 PDGFRB (0.36) DRD2HTR2BPDGFRBPDGFRAEGFR
SCHEMBL719123 0.81 DRD2 (0.44) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL720033 0.77 NCF1 (0.42) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL721292 0.76 PDGFRB (0.60) HTR2BPDGFRBPDGFRAHTR2CHTR2A
SCHEMBL719120 0.76 ALDH1A1 (0.52) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL719753 0.75 HTR2C (0.42) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL722016 0.75 DRD2 (0.40) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL721453 0.72 DRD2 (0.49) DRD2HTR2BADCY6ADCY3ADCY9
SCHEMBL720637 0.72 ADCY6 (0.50) DRD2HTR2BADCY6ADCY3ADCY9
Hydrochloric Acid SCHEMBL722803 0.70 ADCY6 (0.48) DRD2HTR2BADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US claimed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO claimed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA10 DRD2 282/4885HTR2B 268/4885ADCY6 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.